Mateusz Kaczmarek

Mateusz Kaczmarek is a financial and technology journalist at TS2.tech, covering stocks, artificial intelligence, semiconductors and global market developments. A graduate of the Poznań University of Economics and Business, he previously worked in financial analysis before moving into business journalism. His reporting focuses on technology companies, market trends and the forces shaping global investment markets. Follow Mateusz Kaczmarek on Google News.

Blackstone & TPG in $18B Hologic Takeover Shock – Women’s Health Stock Skyrockets

Blackstone & TPG in $18B Hologic Takeover Shock – Women’s Health Stock Skyrockets

Hologic is a Marlborough, MA–based medical technology firm focused on women’s health. Its products include mammography and breast biopsy systems, cervical cancer tests, surgical equipment, and lab diagnostics including molecular tests for Covid-19 bostonglobe.com. The Blackstone/TPG consortium will buy all outstanding Hologic shares for $76 cash plus a $3 CVR marketscreener.com. This values the deal at $79 per share maximum and around $18.3 billion total enterprise value marketscreener.com. The purchase price represents a roughly 46% premium to Hologic’s share price before takeover rumors marketscreener.com.
21 October 2025
····
Billionaire Blowup: NYC’s Catsimatidis Tells Rival to Quit – Pershing Square’s Ackman Admits He “Hates Wasting Money”

Billionaire Blowup: NYC’s Catsimatidis Tells Rival to Quit – Pershing Square’s Ackman Admits He “Hates Wasting Money”

John Catsimatidis has been a longtime supporter of conservative causes. In recent days he threw his weight behind a unified effort to defeat Mamdani by clearing the Republican field. Catsimatidis – who employs Sliwa as a radio host on his WABC station – told reporters that Sliwa should “love New York more than anything else” and drop his mayoral bid to boost Cuomo’s chances abc7ny.com foxnews.com. Catsimatidis claimed New Yorkers would view Sliwa as a hero for “doing the right thing” by quitting abc7ny.com.
21 October 2025
·
Sunrun (RUN) Stock Soars 5% to 12-Month High on Analyst Upgrades and Solar Incentives

Sunrun (RUN) Stock Soars 5% to 12-Month High on Analyst Upgrades and Solar Incentives

On Oct. 21, 2025, Sunrun traded around $20.50, up about 5% intraday reuters.com. This surge followed news that Wall Street’s Citigroup had upgraded Sunrun to “Buy” with a $26 price target marketbeat.com. The stock’s rally pushed it above the consensus 12-month analyst target ts2.tech. In fact, RUN hit a new 12-month high on Oct. 7 markets.financialcontent.com, as investors cheered its improving fundamentals and solar incentives.
21 October 2025
···
AlphaVest (ATMV) Rockets on AMC Robotics Merger Buzz – Key Facts & Forecast

AlphaVest (ATMV) Rockets on AMC Robotics Merger Buzz – Key Facts & Forecast

AlphaVest Acquisition Corp is a special-purpose acquisition company – a “blank check” issuer that raised capital through an IPO to merge with a private company stockanalysis.com globenewswire.com. It has no business operations of its own; its entire asset is cash held in a trust. SPAC shareholders typically get stock in the merged company or can redeem their shares for cash if the deal fails.
21 October 2025
·····
RTX Stock Skyrockets: Aerospace & Defense Boom Sends Q3 Results and 2025 Forecast Soaring

RTX Stock Skyrockets: Aerospace & Defense Boom Sends Q3 Results and 2025 Forecast Soaring

On Oct. 21, RTX reported a blowout quarter. Total sales jumped 12% year-over-year to $22.48 billion globalbankingandfinance.com, handily above the ~$21.3B Wall Street estimate. Adjusted earnings came in at $1.70 per share, well above the consensus ~$1.41 globalbankingandfinance.com investing.com. The results were driven by strength across its portfolio: Collins Aerospace revenues hit $7.62B, and Pratt & Whitney engine sales rose 16% to $8.42B globalbankingandfinance.com. RTX’s defense unit reported a 10% jump in sales, “predominantly from higher sales for its Patriot air defense systems” being used in Ukraine globalbankingandfinance.com. In sum, RTX delivered double-digit organic growth in every segment.
21 October 2025
··
Apple’s iPhone 17 BOOM: Sales Surge, Stock Soars Near $4T – What Analysts Say

Apple’s iPhone 17 BOOM: Sales Surge, Stock Soars Near $4T – What Analysts Say

Apple Inc. is riding high on the strength of its new iPhone 17. Counterpoint Research data show the iPhone 17 line outsold the iPhone 16 series by 14% in their first 10 days on the U.S. and Chinese markets reuters.com investing.com. In particular, the entry-level iPhone 17 has been a smash hit – Chinese demand for the basic model nearly doubled versus last year cnnbrasil.com.br investing.com. Counterpoint senior analyst Mengmeng Zhang credits its “excellent cost-benefit” and strong specs at the same price as 2024 investing.com. As one consumer note, Apple even offered deals and coupons locally to lure buyers. investing.com
21 October 2025
····
Valletta Goes Green: MSC Cruises Powers Up Emission-Free Port Calls

Valletta Goes Green: MSC Cruises Powers Up Emission-Free Port Calls

During Malta’s GreenPort Congress, MSC Cruises held a ceremony celebrating two ships plugging into the new high-voltage shore-power lines at Valletta’s Grand Harbour. On Oct 15 MSC World Europa connected to the grid, and on Oct 16 EXPLORA II did the same mscpressarea.com crew-center.com. This is the first time MSC has achieved consecutive-day shore-power hookups, and makes Explora II the first vessel of its brand to use shoreside electricity in Europe mscpressarea.com crew-center.com. MSC reports its ships have now used Valletta’s shore power for ~300 hours, displacing roughly half a month of emissions that would otherwise be released by idling engines mscpressarea.com.
21 October 2025
·
Lockheed Martin Stock Soars on Earnings Beat – “We’re an arm of the U.S. government,” analyst quips

Lockheed Martin Stock Soars on Earnings Beat – “We’re an arm of the U.S. government,” analyst quips

Lockheed Martin’s Oct. 21 earnings release blew past forecasts, reflecting surging military demand. Revenue rose 8.8% year-over-year to $18.61 billion and net income was $6.95/share seattlepi.com. That beat Wall Street’s $6.33/share estimate and matched analyst forecasts of about $18.56 billion. CEO Jim Taiclet highlighted the “unprecedented demand” for Lockheed products, noting a record $179 billion backlog – over 2½ years of sales news.lockheedmartin.com. In light of the strong quarter, Lockheed raised 2025 guidance. It now expects $22.15–$22.35 EPS and about $74.25–$74.75 billion in revenue reuters.com.
21 October 2025
···
Coca-Cola Crushes Q3 Forecasts as Soda Sales Stay Hot – Stock Jumps

Coca-Cola Crushes Q3 Forecasts as Soda Sales Stay Hot – Stock Jumps

Coca-Cola’s Q3 2025 report blew past Wall Street’s forecasts. The beverage giant logged $12.5 billion in revenue, up 5% from last year stocktitan.net. This exceeded the ~$12.39 billion consensus reuters.com. Volume was flat to slightly positive, but robust price/mix drove growth. As a result, EPS of $0.86 surged 30% year-over-year stocktitan.net, topping the $0.78 street estimate reuters.com by 4 cents. Even excluding special items, Coke’s adjusted EPS of $0.82 comfortably beat forecasts. Notably, operating profit jumped 59% with an operating margin of 32.0% stocktitan.net, reflecting cost control and pricing.
21 October 2025
·
Kraken Lists ASTER: Is This New DeFi Token the Next Big Thing?

Kraken Lists ASTER: Is This New DeFi Token the Next Big Thing?

A deeper look shows Kraken’s move brings a sophisticated DeFi token to its exchange. According to Kraken, ASTER is “a next-gen decentralized exchange offering spot and perpetual trading” across multiple chains blog.kraken.com. Its technology includes MEV-free execution and on-chain perpetuals with innovative collateral features blog.kraken.com binance.com. In practice, Aster lets traders earn yield on collateral like liquid-staked BNB and use a native stablecoin to improve capital efficiency blog.kraken.com. In early October 2025, Binance also listed ASTER binance.com, and now Kraken has added it, widening access for traders on both platforms.
21 October 2025
··
Lynas Rare Earths (LYSCF) Stock Soars on $8.5B U.S.–Australia Rare-Earth Pact

Lynas Rare Earths (LYSCF) Stock Soars on $8.5B U.S.–Australia Rare-Earth Pact

Lynas shares have been on a tear. By mid-October 2025, the stock had nearly tripled in a year Investing ts2.tech. In early October it spiked to A$21.96 Investing on the magnet-chain MoU, then eased back to ~$18–19 as traders locked in profits ts2.tech. In late Oct 20–21 trading it jumped again Stockanalysis. By Oct 21 LYC was ~A$19 Investing Stockanalysis. The OTC ADR mirrors this: it closed at US$14.00 on Oct 20 Stockanalysis.
21 October 2025
··
Stratasys (SSYS) Stock Surges 14%: Why 3D Printing Shares Are Heating Up

Stratasys (SSYS) Stock Surges 14%: Why 3D Printing Shares Are Heating Up

In summary, Stratasys’s stock has surged to multi-month highs on a combination of company-specific catalysts and broader market tailwinds. Recent acquisitions, strategic partnerships, and solid quarterly results have helped offset lingering macro uncertainty. Analysts remain cautious, but insiders emphasize that the core additive-manufacturing trend remains intact 3dprint.com investors.stratasys.com. With the U.S. manufacturing cycle poised for recovery and Fed policy possibly loosening, many experts see potential upside for SSYS in late 2025 and beyond – though they warn that customer spending could stay restrained until the economy stabilizes finviz.com investors.stratasys.com.
21 October 2025
·
Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Ticker: Beam Therapeutics globenewswire.com. – Price: ~$30 per share ts2.tech. – Sector: Biotechnology globenewswire.com. – Recent News: FDA granted Regenerative Medicine Advanced Therapy and Orphan Drug designations to Beam’s lead programs globenewswire.com stocktitan.net. Early trial data for these programs have been promising. – Analyst Outlook: Consensus is “Moderate Buy” with average 1-year target ~$45–46 marketbeat.com nasdaq.com, implying roughly 70–80% upside.
21 October 2025
··
DocGo (NASDAQ: DCGO) Stock Rockets After Virtual Care Acquisition – Can the Rally Last?

DocGo (NASDAQ: DCGO) Stock Rockets After Virtual Care Acquisition – Can the Rally Last?

DocGo’s shares jumped more than 34% in after-hours trading on Oct. 20, 2025, after the company announced it would acquire SteadyMD, a virtual care platform. According to an Investing.com report, DocGo stock “surged 34.6% in after-hours trading Monday following the company’s announcement that it has acquired virtual care platform SteadyMD” m.uk.investing.com. The acquisition was disclosed on Monday, Oct. 20, and a conference call to discuss it was scheduled for Oct. 21.
21 October 2025
·
SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

stockanalysis.com stockanalysis.com Spero’s shares have roughly doubled this year, hitting around $2.29 on Oct 20, 2025. The stock has traded in a broad range stockanalysis.com. Trading volume is light, and the stock’s beta indicates volatility. In recent days, SPRO has climbed on the back of the Phase 3 data. The 50-day moving average and 200-day average suggest the trend has turned positive after the spring rally. Year-to-date, SPRO is up ~120%, well above the small-cap biotech average.
21 October 2025
···
Replimune Stock Rockets 100% on FDA Nod – Analysts Eye Upside

Replimune Stock Rockets 100% on FDA Nod – Analysts Eye Upside

Replimune’s stock has been extremely volatile in 2025. It soared on Oct. 20 after the FDA acceptance news: shares nearly doubled from about $4.50 to $8.94 that day marketbeat.com. This reversed a mid-year collapse – in July 2025 a disappointing FDA Complete Response Letter caused the stock to collapse ~73% in one day globenewswire.com. Over the past year the 52-week trading range is roughly $2.68 to $17.00 marketbeat.com, reflecting that roller-coaster.
21 October 2025
·
1 … 92 93 94 95 96 … 164

Stock Market Today

  • 3M (MMM) Jumps 8.5% After Higher 2026 EPS Outlook
    July 26, 2026, 11:19 AM EDT. 3M (NYSE:MMM) stock climbed 8.5% to $172.62, pushing its market cap to approximately $89.7 billion in the wake of its Q2 report. The company lifted its adjusted EPS outlook by 3.2% to $8.80-$8.95, bringing the P/E ratio to 19.4 times. Q2 organic sales advanced 5.4%, EPS surpassed estimates at $2.40, and gains were led by Safety, Industrial, Transportation, and Electronics units. The valuation rose following $3 billion in stock repurchases.